发明名称 |
HLA-restricted, peptide-specific antigen binding proteins |
摘要 |
Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. |
申请公布号 |
US9453075(B2) |
申请公布日期 |
2016.09.27 |
申请号 |
US201414299509 |
申请日期 |
2014.06.09 |
申请人 |
MEMORIAL SLOAN-KETTERING CANCER CENTER |
发明人 |
Cheung Nai-Kong;Tassev Dimiter;Hu Jian |
分类号 |
C07K16/28;C07K16/08;C07K16/18;A61K39/00 |
主分类号 |
C07K16/28 |
代理机构 |
Heslin Rothenberg Farley & Mesiti P.C. |
代理人 |
Heslin Rothenberg Farley & Mesiti P.C. ;Smith Dias Kathy |
主权项 |
1. An antigen-binding protein comprising one of:
(A) an antigen binding region having the amino acid sequence of SEQ ID NO: 5; (B) an antigen binding region comprising a VH and a VL respectively, with the amino acid sequences SEQ ID NOs: 24 and 25; or (C) (i)
(a) a light chain (LC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 56;(b) a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 58; and(c) a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 65; and
(ii) (a) a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 39;
(b) a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 41; and(c) a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 49. |
地址 |
New York NY US |